628 related articles for article (PubMed ID: 21790210)
1. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S
Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
4. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
Sanford M
Drugs; 2014 Aug; 74(12):1411-33. PubMed ID: 25063048
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod is a potential novel therapy for multiple sclerosis.
Aktas O; Küry P; Kieseier B; Hartung HP
Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
[TBL] [Abstract][Full Text] [Related]
12. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
18. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
Tanasescu R; Constantinescu CS
Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
